Clinical Trial

Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to explore the efficacy and safety of radiotherapy combined with immunotherapy in the neoadjuvant treatment of resectable NSCLC.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-25; most recent amendment 2026-01-08.
Status change: Not Yet Recruiting → Recruiting 2025-07-08
Trial Details
NCT Number NCT07050056
Lead Sponsor Northern Jiangsu People's Hospital
Conditions Resectable NSCLC
Enrollment 20 participants
Start Date 2025-08-01
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-09